Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biosource International -- Ignore unavailable to you. Want to Upgrade?

To: Joe Dancy who wrote (528)	7/17/1998 10:44:00 PM
From: milton	Read Replies (2) \| Respond to of 696

Joe Dancy Does this mean that 20X or 30X we are looking at $10 to $15? What do you think?

To: Joe Dancy who wrote (528)	8/22/1998 10:53:00 AM
From: Dowscanner	Respond to of 696

Thoughts about earnings for next few quarters. The accelerated research and development investment will allow BioSource International to introduce two new product lines in the second half of this year, including a family of reagents and test kits to study apoptosis, and a line of bulk reagents or researchers designing quantitative human cytokine assays," said James H. Chamberlain, chairman, president and chief executive officer of BioSource International. "We're excited by the market potential for both product lines and believe they will generate profitable new revenue in 1999 that will more than offset the incremental R&D investment." June 6 1997 Chamberlain noted that approximately one-half of the Company's sales revenue is generated in Europe, and emphasized the Company's belief that the shortfall is primarily the result of exchange rate differences. Does anyone know how the exchange rate has changed since June 97? Sales in Europe are typically slower in summer and therefor may have less impact on next quarters earnings when compared yr/yr. Slower summer sales will have a negative impact on earnings when compared last quarter to next.